300765 Cspc Innovation Pharmaceutical Co.,Ltd.
Closed 08-19 15:00:00
43.15
-1.25
-2.82%
High44.49Low42.34Vol24.61M
Open44.08D1 Closing44.40Amplitude4.84%
Mkt Cap60.63BTradable Cap60.63BTotal Shares1.41B
T/O1.07BT/O Rate1.75%Tradable Shares1.41B
P/B15.84ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

CSPC Innovation Subsidiary Initiates Phase Ib/II Clinical Trial for SYS6090
Stock News  ·  08-19 16:04
CSPC Innovation Subsidiary Initiates Phase Ib/II Clinical Trial for SYS6090
CSPC Innovation Posts RMB 1.26 Billion H1 Net Profit on RMB 3.24 Billion Revenue
Reuters  ·  08-17 20:19
CSPC Innovation Posts RMB 1.26 Billion H1 Net Profit on RMB 3.24 Billion Revenue
Cspc Innovation Pharmaceutical Reports Net Profit of 1.261 Billion Yuan in First Half After Turning Losses Around
Stock News  ·  08-17 16:51
Cspc Innovation Pharmaceutical Reports Net Profit of 1.261 Billion Yuan in First Half After Turning Losses Around
CSPC Innovation Pharmaceutical H1 Net Profit 1.3 Billion Yuan
Reuters  ·  08-17 16:49
CSPC Innovation Pharmaceutical H1 Net Profit 1.3 Billion Yuan
CSPC Innovation Pharmaceutical H1 Net Profit 1.3 Bln Yuan
THOMSON REUTERS  ·  08-17 16:33
CSPC Innovation Pharmaceutical H1 Net Profit 1.3 Bln Yuan
CSPC Innovation Pharmaceutical Gets $30 Million Initial Payment for Nucleic Acid Development Deal With AstraZeneca
MT Newswires Live  ·  08-13
CSPC Innovation Pharmaceutical Gets $30 Million Initial Payment for Nucleic Acid Development Deal With AstraZeneca
Cspc Innovation's Subsidiary Receives $30 Million Upfront Payment from AstraZeneca
Stock News  ·  08-12
Cspc Innovation's Subsidiary Receives $30 Million Upfront Payment from AstraZeneca
CSPC Innovation Pharmaceutical Unit Receives FDA Clearance for Monkeypox Vaccine Trial; Shares Up 6%
MT Newswires Live  ·  08-11
CSPC Innovation Pharmaceutical Unit Receives FDA Clearance for Monkeypox Vaccine Trial; Shares Up 6%
Cspc Innovation Subsidiary Gets FDA Clearance for Monkeypox mRNA Vaccine Trial
Stock News  ·  08-10
Cspc Innovation Subsidiary Gets FDA Clearance for Monkeypox mRNA Vaccine Trial
CSPC Innovation Pharmaceutical Launches Phase Ib/II Trial for Colorectal Cancer Drug
MT Newswires Live  ·  08-04
CSPC Innovation Pharmaceutical Launches Phase Ib/II Trial for Colorectal Cancer Drug
Cspc Innovation Pharmaceutical Initiates Phase Ib/II Trial for SYS6090 Combination Therapy
Stock News  ·  08-03
Cspc Innovation Pharmaceutical Initiates Phase Ib/II Trial for SYS6090 Combination Therapy
Cspc Innovation Pharmaceutical's Subsidiary Launches Phase II Trial for SYS6041
Stock News  ·  07-31
Cspc Innovation Pharmaceutical's Subsidiary Launches Phase II Trial for SYS6041
CSPC Innovation Pharma Subsidiary Gets FDA Clinical Trial Approval for CRB-701 Cancer Drug; Shares Slide 4%
MT Newswires Live  ·  07-30
CSPC Innovation Pharma Subsidiary Gets FDA Clinical Trial Approval for CRB-701 Cancer Drug; Shares Slide 4%
Cspc Innovation Subsidiary's Licensed Drug CRB-701 (SYS6002) Gets FDA Nod for Phase 3 Trial in Second-Line Oropharyngeal Cancer
Stock News  ·  07-29
Cspc Innovation Subsidiary's Licensed Drug CRB-701 (SYS6002) Gets FDA Nod for Phase 3 Trial in Second-Line Oropharyngeal Cancer
Cspc Innovation Pharmaceutical forecasts net profit of 1.18 to 1.36 billion yuan for first half of 2026, reversing year-on-year loss
Stock News  ·  07-27
Cspc Innovation Pharmaceutical forecasts net profit of 1.18 to 1.36 billion yuan for first half of 2026, reversing year-on-year loss
CSPC Innovation Pharma, CSPC Pharmaceutical Group Unit, Forecasts H1 Net Profit at 1.18 Billion-1.36 Billion Yuan
Reuters  ·  07-27
CSPC Innovation Pharma, CSPC Pharmaceutical Group Unit, Forecasts H1 Net Profit at 1.18 Billion-1.36 Billion Yuan
CSPC Innovation Pharmaceutical Receives China Approval for SYS6043 Clinical Trial; Shares Slide 4%
MT Newswires Live  ·  07-17
CSPC Innovation Pharmaceutical Receives China Approval for SYS6043 Clinical Trial; Shares Slide 4%
CSPC Innovation Pharmaceutical's Subsidiary Initiates Phase III Trial for SYS6043
Stock News  ·  07-16
CSPC Innovation Pharmaceutical's Subsidiary Initiates Phase III Trial for SYS6043
Resolutions Passed at CSPC Innovation Pharmaceutical's Third Extraordinary Shareholders' Meeting of 2026
Deep News  ·  07-08
Resolutions Passed at CSPC Innovation Pharmaceutical's Third Extraordinary Shareholders' Meeting of 2026
CSPC Innovation Pharmaceutical's Investigational Drug SYS6043 Granted Breakthrough Therapy Designation
Stock News  ·  07-02
CSPC Innovation Pharmaceutical's Investigational Drug SYS6043 Granted Breakthrough Therapy Designation

Introduction

Company Name.
石药创新制药股份有限公司
Industry:
食品制造业
Listing Date:
2019-03-22
Main Business:
　　石药创新制药股份有限公司的主营业务是生物制药、功能性原料及保健食品的研发、生产与商业化。公司的主要产品是抗体药物、ADC药物、mRNA疫苗、药品、咖啡因、阿卡波糖、无水葡萄糖原料及果维康维生素C含片、维生素B族含片。公司是国内首批实现mRNA疫苗产业化、ADC与抗体药物管线布局最完整的创新型生物药企业之一，已发展成为集源头创新、临床转化、规模生产与国际商业化于一体的高新技术企业。
Issue price:
24.47